| Old Articles: <Older 3351-3360 Newer> |
|---|
 |
The Motley Fool
December 26, 2006
Brian Lawler |
Bristol-Myers in the Giving Spirit The pharmaceutical finally settled with the U.S. DOJ and various state attorneys general over allegations that it was artificially inflating stated wholesale drug prices in order to gouge consumers and government health-care programs. What does it mean to investors?   |
The Motley Fool
December 22, 2006
Stephen Albainy-Jenei |
Is Off-Label Off-Base? Off-label prescriptions for uses lacking scientific support account for billions in drug revenue for Eli Lilly. If the FDA takes an aggressive stance on off-label-use marketing, it could significantly shrink drug sales for companies whose revenues are derived largely from such off-label use. |
The Motley Fool
December 20, 2006
Billy Fisher |
Northfield Shares Head South Anemic results for a blood substitute leave shares run down. |
The Motley Fool
December 19, 2006
Brian Gorman |
Novartis Cuts in Line at the Drugstore Consolidation in pharmacy benefits management may leave Novartis most resistant to pricing pressure. Investors, take note. |
BusinessWeek
December 25, 2006
Palmeri & Weintraub |
Silicone Goes Subtle Allergan's campaign relies on friendly persuasion. |
The Motley Fool
December 15, 2006
Brian Lawler |
Reformatting Encysive Yet another delay from the FDA leaves investors hanging. |
The Motley Fool
December 14, 2006
Brian Lawler |
Celgene Faces a Generic Challenge An abbreviated application is only an opening salvo in Barr's challenge to Celgene's Thalomid patents. Investors, take note. |
The Motley Fool
December 14, 2006
Brian Lawler |
Vertex: Coming Together Nicely If telaprevir continues to show anything like the 80%-90% rate of undetectable hepatitis C virus at end of its trials, Vertex shareholders won't be dealing with too many more down days. |
The Motley Fool
December 14, 2006
Stephen Albainy-Jenei |
Merck Gets Punk'd by Thailand Thailand issues a compulsory license to manufacture a generic version of Merck's patented AIDS drug. This is an act of humanitarian aid, but it is also an avenue for price and profit erosion worldwide. |
The Motley Fool
December 13, 2006
Jeremy MacNealy |
Johnson & Johnson: Scrooge or Santa? Here is a closer look at Johnson & Johnson and how the company is trying to make a positive contribution to the world. Shareholders and employees alike should be proud that the company is a model corporate citizen for other companies to follow. |
| <Older 3351-3360 Newer> Return to current articles. |
